Skip to main content
Bristol Myers SquibbEarnings

Bristol-Myers Squibb Beat Estimates but Cut EPS Guidance in Q3 2026

Source: Autobound Signal API · 117 signals tracked for Bristol Myers Squibb · updated

Get Bristol Myers Squibb's live signals in Claude or ChatGPT, or by API

AskWhat changed at Bristol Myers Squibb this week? Use Autobound signals for bms.com.

What happened

Bristol-Myers Squibb reported Q3 2026 adjusted EPS of $1.35, beating expectations.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

As seen on the 24/7 Wall St. homepage on October 29, 2026. Bristol Myers Squibb cut full-year adjusted EPS guidance to $6.35 to $6.55 from $6.75 to $7.00 even though both lines topped expectations, a split driven by acquired IPRD charges while the revenue outlook went up. Keep an eye on the stock as investors weigh the dealmaking hit. Bristol-Myers Squibb posted adjusted EPS of $1.35 in Q3 2026, beating expectations for a sixth straight quarter. Acquired IPRD charges of $1.56 billion are the direct reason management trimmed full-year non-GAAP EPS guidance, even as the revenue outlook moved higher. Eliquis was the standout, growing 25% worldwide on strong U.S. demand, while generic competition kept carving up legacy drugs such as Revlimid and Pomalyst/Imnovid. Sponsored CEO Christopher Boerner highlighted the recent FDA approval of Zenbexus, a first-in-class CELMoD for multiple myeloma, with Phase 3 PFS data and a mezigdomide PDUFA date set for May 13, 2027 still ahead. Share repurchase authorization of roughly $5 billion remains, so the balance sheet still has tools available against a lower EPS guide driven by deal-related charges. Mentioned: BMY, BMYMP

247wallst.com/cards/bristol-myers-squibb-q3-2026-earnings-bmy-01m63nw...Read the full source

Extracted by Autobound

From the Signal API record
Event
Earnings

What this signalsEarnings results often set the next budget cycle.

The full record

From the Signal API record

Numbers

Amount (USD)
$1

Extraction

Confidence
95%
Detected
Oct 29, 2026
signal_type
news
signal_subtype
has_earnings

Use this data

Get every earnings signal for Bristol Myers Squibb and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Bristol Myers Squibb this week?”

  2. Send it to your own tools

    The Signal API returns earnings signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/94ad4d04-eb6b-25ff-13b8-8c2b4498bbaf returns this record as JSON. POST /v1/companies/enrich returns every signal for bms.com.

{
  "signal_id": "94ad4d04-eb6b-25ff-13b8-8c2b4498bbaf",
  "signal_type": "news",
  "signal_subtype": "has_earnings",
  "detected_at": "2026-10-29T11:28:32+00:00",
  "company": {
    "name": "Bristol Myers Squibb",
    "domain": "bms.com"
  },
  "data": {
    "url": "https://247wallst.com/cards/bristol-myers-squibb-q3-2026-earnings-bmy-01m63nw8rj7epy0b0sqaan4rrd",
    "title": "Bristol-Myers Squibb Beat Estimates but Cut EPS Guidance in Q3 2026 - 24/7 Wall St.",
    "excerpt": "As seen on the 24/7 Wall St. homepage on October 29, 2026. Bristol Myers Squibb cut full-year adjusted EPS guidance to $6.35 to $6.55 from $6.75 to $7.00 even though both lines topped expectations, a split driven by acquired IPRD charges while the revenue outlook went up. Keep an eye on the stock as investors weigh the dealmaking hit. Bristol-Myers Squibb posted adjusted EPS of $1.35 in Q3 2026, beating expectations for a sixth straight quarter. Acquired IPRD charges of $1.56 billion are the direct reason management trimmed full-year non-GAAP EPS guidance, even as the revenue outlook moved higher. Eliquis was the standout, growing 25% worldwide on strong U.S. demand, while generic competition kept carving up legacy drugs such as Revlimid and Pomalyst/Imnovid. Sponsored CEO Christopher Boerner highlighted the recent FDA approval of Zenbexus, a first-in-class CELMoD for multiple myeloma, with Phase 3 PFS data and a mezigdomide PDUFA date set for May 13, 2027 still ahead. Share repurchase authorization of roughly $5 billion remains, so the balance sheet still has tools available against a lower EPS guide driven by deal-related charges. Mentioned: BMY , BMYMP",
    "summary": "Bristol-Myers Squibb reported Q3 2026 adjusted EPS of $1.35, beating expectations.",
    "planning": false,
    "image_url": "https://247wallst.com/og/card/01m63nw8rj7epy0b0sqaan4rrd.png",
    "confidence": 0.95,
    "published_at": "2026-10-29T11:28:32Z",
    "article_sentence": "Bristol-Myers Squibb posted adjusted EPS of $1.35 in Q3 2026, beating expectations for a sixth straight quarter.",
    "amount_normalized": 1
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.